Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The leukemic stem cell.

Craig T Jordan1

  • 1James P. Wilmot Cancer Center, University of Rochester School of Medicine, 601 Elmwood Ave, Box 703, Rochester, NY 14642, USA. craig_jordan@urmc.rochester.edu

Best Practice & Research. Clinical Haematology
|March 6, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Dual targeting of SLC25A51 and succinate dehydrogenase selectively depletes mitochondrial NAD<sup>+</sup> to eradicate KRAS-driven AML.

Cell metabolism·2026
Same author

The Nicotinamide Salvage Pathway is a Metabolic Vulnerability of High-Risk MDS Stem Cells.

bioRxiv : the preprint server for biology·2026
Same author

Targeting IL-1/IRAK1/4 signaling in acute myeloid leukemia stem cells following treatment and relapse.

Leukemia·2025
Same author

Development of a Dynamic Counterfactual Risk Stratification Strategy for Newly Diagnosed Patients With AML Treated With Venetoclax and Azacitidine.

JCO clinical cancer informatics·2025
Same author

A generalized strategy to kill leukemic cells by targeting the regulatory systems governing mitochondrial membrane potential.

Cell reports·2025
Same author

Omacetaxine and azacitidine for untreated patients with myelodysplastic syndromes and excess blasts: a phase I/II clinical trial.

EClinicalMedicine·2025
Same journal

CAR-T cell therapy for multiple myeloma: An update on the current state and future potential.

Best practice & research. Clinical haematology·2025
Same journal

Cancer vaccines in hematologic malignancy: A systematic review of the rational and evidence for clinical use.

Best practice & research. Clinical haematology·2025
Same journal

Immune therapy of haematological cancers.

Best practice & research. Clinical haematology·2025
Same journal

Advances in NK cell therapy for multiple myeloma.

Best practice & research. Clinical haematology·2025
Same journal

Adoptive cellular therapies in multiple myeloma.

Best practice & research. Clinical haematology·2025
Same journal

Bispecific T-cell engager therapy for multiple myeloma.

Best practice & research. Clinical haematology·2025
See all related articles

Malignant stem cells drive cancer, but current chemotherapy harms both cancerous and healthy stem cells. New therapies like parthenolide and TDZD-8 specifically target cancer stem cells, offering potential cures.

Area of Science:

  • Oncology
  • Stem Cell Biology
  • Cancer Research

Background:

  • Malignant stem cells are identified as the origin of various human cancers.
  • These cells are rare and exhibit distinct properties compared to other tumor cells.
  • Current chemotherapy is ineffective against leukemic stem cells due to targeting of both normal and malignant stem cells.

Purpose of the Study:

  • To explore novel therapeutic strategies targeting malignant stem cells.
  • To identify agents that specifically target cancer stem cells while sparing normal stem cells.
  • To summarize recent advancements in leukemic stem cell research and discuss future therapeutic directions.

Main Methods:

  • Review of preclinical data on agents targeting leukemic stem cells.
  • Analysis of the distinct properties of malignant stem cells.

Related Experiment Videos

  • Discussion of potential new therapeutic strategies and combinations.

    • Main Results:

    • Parthenolide (feverfew) and TDZD-8 show lethality against leukemic stem cells in preclinical studies.
    • These agents have undergone preclinical development but have not yet been used in cancer patients.
    • The distinct properties of malignant stem cells necessitate targeted therapeutic approaches.

    Conclusions:

    • Targeting leukemic stem cells specifically is crucial for effective leukemia treatment.
    • Agents like parthenolide and TDZD-8 hold promise for eradicating cancer stem cells.
    • Combinations of existing therapies and novel agents may offer a cure for leukemia.